Group 1E: Metastatic Breast Cancer; ER+; Novel Drug

Poster #P3-03-23: Targeting of SEMA7A Signaling Improves Response to Endocrine Therapy in ER+ BC

Poster #P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Advanced or Metastatic Breast Cancer: TACTIVE-U  Prelim Phase 1b Results